Evidence map›Paper›PMID 39767178›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Prognostic Factors for Cancer-Specific Survival and Disease-Free Interval in 130 Patients with Follicular Thyroid Carcinoma: Single Institution Experience.

Matija Buzejic, Zoran Bukumiric, Branislav Rovcanin, Milan Jovanovic, Marina Stojanovic, Goran Zoric, Katarina Tausanovic, Nikola Slijepcevic, Vladan Zivaljevic

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matija BuzejicClinic for Endocrine Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0001-5580-3247
Zoran BukumiricInstitute of Medical Statistics and Informatics, School of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-7609-4504
Branislav RovcaninClinic for Endocrine Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0002-8099-3764
Milan JovanovicClinic for Endocrine Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0002-0118-8450
Marina StojanovicSchool of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Goran ZoricClinic for Endocrine Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Katarina TausanovicClinic for Endocrine Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Nikola SlijepcevicClinic for Endocrine Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0002-3999-1062
Vladan ZivaljevicClinic for Endocrine Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFollicular thyroid carcinoma (FTC) is categorized into three groups: minimally invasive FTC (MIFTC), encapsulated angioinvasive FTC (EAIFTC), and widely invasive FTC (WIFTC). FTC is the second most common type of thyroid tumor, though it remains relatively rare in the general population. This study aimed to examine the prognosis and prognostic factors in patients with follicular thyroid carcinoma.

methodsData were obtained from a tertiary referral center for 130 FTC patients, covering the period from 1995 to 2020. Clinical data included demographic characteristics, tumor features, type of surgery, tumor recurrence, and vital status. Descriptive statistical methods, Kaplan-Meier survival curves, and Cox proportional hazard regression were used for statistical analysis to identify independent predictors.

resultsDistant metastases occurred in 12 patients during the follow-up period. The 5-year, 10-year, 15-year, and 20-year cancer-specific survival (CSS) rates were 98.1%, 92.3%, 83.5%, and 79.8%, respectively. Independent unfavorable prognostic factors for CSS included widely invasive tumor type (hazard ratio [HR] 3.63, 95% CI 1.29-10.18), multifocality (HR 6.7, 95% CI 1.37-32.72), and presence of distant metastases (HR 2.29, 95% CI 1.08-4.84). When disease-free interval (DFI) was considered, the 5-year, 10-year, 15-year, and 20-year rates were 92.3%, 85.3%, 82.0%, and 76.6%, respectively. Independent unfavorable prognostic factors for DFI were widely invasive tumor type (HR 2.53, 95% CI 1.02-6.28) and tumor multifocality (HR 7.69, 95% CI 1.07-55.17).

conclusionsThe 10-year survival rate for patients with FTC is relatively favorable. Factors associated with poorer prognosis include the presence of distant metastases, WIFTC, and multifocality. Factors linked to disease recurrence are WIFTC and multifocality.

Indexed as

cancer-specific survivaldisease-free intervalfollicular thyroid cancer

Identifiers

PMID39767178
PMCPMC11675052

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.